DOCSLIB.ORG

Tuesday, December 13, 2005 Poster Session II

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Tuesday, December 13, 2005 Poster Session II Neuropsychopharmacology (2005) 30, S143-S209 © 2005 Nature Publishing Group All rights reserved 0893-133X/05 www.neuropsychopharmacology.org S143 Tuesday, December 13, 2005 the context of cocaine delivery can alter the neurochemical responses to Poster Session II - Tuesday the drug. In addition, increasing evidence suggests that stress can also in- fluence COC reinforcement through extrahypothalamic brain regions. The present study was designed to determine differences in the neuro- 1. Diffusion Tensor Imaging in Cocaine Dependence: Evidence for chemical and neuroendocrine responses to COC during response-con- Reduced Myelin in the Anterior Corpus Callosum tingent and response-independent COC administration in rats. F. Gerard Moeller*, Khader M Hassan, Joel L Steinberg, Ignacio Methods: Male Wistar rats were divided into triads of 3 rats each: Valdes, Larry Kramer, Ponnada A Narayana and Alan C Swann one rat was selected as the self-administration (SA) rat, while the Psychiatry and Behavioral Sciences, Univ. of Texas Health Sci. Center other two rats were designated as the yoked-cocaine (YC) and yoked- at Houston, Houston, TX, USA saline (YS) rats, respectively. Rats were implanted with jugular Sponsor: Alan Swann catheters and a microdialysis guide cannula aimed at the medial pre- frontal cortex (MPC). SA rats were trained to self-administer cocaine Background: Fractional anisotropy (FA) as measured by diffusion (0.25 mg/kg/inf) under a fixed-ratio 2 schedule of reinforcement; 20- tensor imaging (DTI) is becoming increasingly used as a measure min samples were collected 2 hrs prior to, during and after the SA of subtle white matter pathology in psychiatric populations. How- session. ever, diffusion anisotropy is affected both by the state of myelin Results: DA and norepinephrine (NE) concentrations in the micro- and axonal structure and therefore lacks pathologic specificity. Ev- dialysates from the MPC were significantly elevated in SA and YC idence has been accumulating that the individual eigenvalues, groups during the SA session. Similar results were observed for DA which represent diffusion along the fiber track (λ 1) or perpendi- in the amygdala. The increases in DA and NE levels in the MPC cular to the fiber track (λ2), provide enhanced pathologic speci- during the session were greater in the YC group compared to the SA ficity compared to anisotropic and mean diffusivity indices. The group. Moreover, the duration of the DA response in the MPC was purpose of this study was to compare cocaine dependent subjects greater in the YC group vs. the SA group. We did not find significant with non-drug using controls using individual DTI eigenvalues. differences in DA levels between the SA and YC groups in the amyg- Methods: Eighteen cocaine dependent subjects and 18 healthy controls dala. To determine the effects of self-administered COC on corti- underwent full brain Diffusion tensor imaging (DTI) acquired with a dif- costerone (CORT), the hormone was measured in the MPC using in fusion sensitized dual spin echo prepared echoplanar imaging (SE-EPI) vivo microdialysis. Dialysates were analyzed for CORT by radioim- sequence, on a 1.5 T General Electric echospeed CNV MRI scanner using munoassay (RIA). Baseline MPC CORT was low and stable in all a standard quadrature RF Head Coil. The diffusion tensor encoding groups prior to the start of the SA session and remained stable scheme was based on the uniformly distributed and balanced rotation- throughout the entire experiment in the YS rats, suggesting that the ally invariant Icosa21 tensor encoding set. Fast spin echo proton density procedure itself was not stressful. MPC CORT was significantly ele- and T2 weighted images were acquired from the same location as DTI. vated in the microdialysates from the SA rats during SA (269% in- DTI post processing was performed using the Automated Image Regis- crease), while MPC CORT was increased 553% above baseline in tration (AIR) package. The distortion corrected images were decoded the YC rats. MPC CORT was significantly higher in the YC com- using a least squares singular value decomposition approach to estimate pared to the SA rats. Plasma CORT and ACTH were higher in YC the diffusion tensor elements. The corpus callosum was the focus of this group than in the SA and YS groups prior to the beginning of the analysis, which was divided into 7 segments based on the previous work SA sessions. by Witelson (1989) in order to compare regions of the corpus callosum Discussion: It has been suggested that one of the numerous mole- and thereby examine fiber tracts linked to different cortical regions. All 7 cules involved in stress response pathways is P-gp (glycoprotein) or segments of the corpus callosum were compared between cocaine users MDR1 efflux transporter. MDR1a is found in vascular endothelial and controls for using a Mixed Model ANOVA for λ1 and λ2. cells and is active at the blood-brain barrier, whereas MDR1b is Results: Results showed a significant increase in λ2inthegenu of the found mainly in astrocytes and microglia. We tested the hypothesis anterior corpus callosum in cocaine dependent subjects compared to that MDR1 genes respond differentially to SA vs. YC administra- controls. Within cocaine dependent subjects there was a significant tion. We found that levels of the MDR1a, but not MDR1b, tran- positive correlation between years of cocaine use and λ2. There was no scripts were higher in each of the SA animals compared to its re- significant difference between groups for λ 1. spective YC control. We are currently replicating and extending Discussion: Twoprior studies found reductions in FA in cocaine de- these preliminary findings and, if upheld, these data may suggest pendent subjects on DTI (Lim et al., 2002, Moeller et al., 2005). How- the possibility that the MDR1a gene contributes to the reduced ever, based on reduced FA value, it is difficult to determine whether de- toxicity in SA relative to YC rats. These results suggest that the con- myelination or axonal injury is responsible for the fiber tract damage. text in which cocaine is administered can alter the neurochemical Based on prior animal and human studies suggesting that demyelination and neuroendocrine responses to cocaine. Furthermore, CORT in increases diffusion normal to the direction of fiber tracts λ2with mini- the MPC may mediate neurobiological responses involved in COC mal effect on λ1 our findings are consistent with a reduction in myelin in reinforcement. the anterior corpus callosum in cocaine dependent subjects. These re- sults will be discussed in light of other studies showing evidence of frontal-subcortical dysfunction in cocaine dependent subjects. 3. Decreased Corticolimbic Responset To Monetary Reward in Cocaine Addiction: Association with Motivation and Self-Control Rita Z Goldstein*, Dardo Tomasi, Nelly Alia-Klein, Lisa A Cottone, 2. Effects of Self-Administered and Passive Cocaine Infusions on Lei Zhang, Thomas Maloney, Frank Telang, Elisabeth C Caparelli, Dopamine, Norepinephrine and Corticosterone Concentrations in James M Swanson and Nora D Volkow the Medial Prefrontal Cortex Nicholas E Goeders*, Gennady N Smagin, Marie F Lanfranco, Medical Research, Brookhaven National Laboratory, Upton, NY, USA Patricia K Seitz, Mary L Thomas, Kathryn A Cunningham and Vitaly Sponsor: James Swanson S Palamarchouk Background: Our objective was to study the role of the corticolimbic Pharmacology, Toxicology & Neuroscience, LSU Health Sciences reward circuit in sensitivity to reward/motivation and inhibitory con- Center, Shreveport, LA, USA trol in cocaine addiction. Background: Cocaine (COC) reinforcement is widely accepted to be Methods: Sixteen cocaine users and 12 healthy controls performed a mediated via the mesocorticolimbic dopamine (DA) system. However, delayed forced-choice task under three blocked monetary value ACNP 2005 Annual Meeting S144 conditions (high money=45 cents, low money=1 cent, no HPA axis hormones. Because nalbuphine has both mu and kappa ac- money=0) while brain activation was measured with BOLD fMRI. tivity, its endocrine effects are not predictable from data on the effects State measures of motivation on this incentive fMRI task were as- of mu or kappa opioids alone. sessed objectively by speed (reaction time) and accuracy of re- Methods: We examined the effects of two analgesic doses of nalbuphine sponses (percent correct), and on a subjective level as self-reported on prolactin, ACTH and cortisol in 10 healthy male volunteers with a engagement in this task. Inhibitory control was assessed by trait es- history of current cocaine abuse (DSM-IV, 305.6). Subjects provided timates from a personality questionnaire (Tellegen’s Multidimen- informed consent for participation in these studies. Nalbuphine (5 sional Personality Questionnaire, MPQ, Self Control scale) and by mg/70 kg, IV) was administered to 7 men and 10 mg/70 kg, IV was ad- state estimates from a conflict task (Fan’s Attention Network Task, ministered to 3 men. Blood samples were collected 30 and 5 min before ANT, Conflict scale). nalbuphine infusion, and 13 blood samples were collected at 10, 17, 19, Results: The manipulated independent variable (monetary value) 23, 27, 31, 35, 40, 45, 60, 75, 105, 135 min after nalbuphine administra- produced a differential pattern of neural response (fMRI signal tion. Heart rate and blood pressure were monitored and subjective ef- change) in healthy controls: there was a trend in the orbitofrontal fects of nalbuphine were measured on a Visual Analog Scale (VAS). cortex (OFC) to respond in a graded fashion (45>1>0), the ante- Results: Significant nalbuphine dose-related increases in prolactin rior cingulate gyrus (ACG) and cerebellum responded to the two occurred within 17 min (P=.04). Peak prolactin levels of 22.1 ± 7.1 conditions of monetary value equally (45=1>0), and the mesen- ng/ml and 54.1 ± 11.3 ng/ml were measured at 60 min after low and cephalon responded to the highest available reward only high dose nalbuphine administration, respectively.
Load more

Recommended publications
  • Dopamine Reuptake Transporter (DAT) “Inverse Agonism” E Anovel 66 2 67 3 Hypothesis to Explain the Enigmatic Pharmacology of Cocaine 68 4 * 69 5 Q5 David J
    NP5526_proof ■ 24 June 2014 ■ 1/22 Neuropharmacology xxx (2014) 1e22 55 Contents lists available at ScienceDirect 56 57 Neuropharmacology 58 59 60 journal homepage: www.elsevier.com/locate/neuropharm 61 62 63 64 65 1 Dopamine reuptake transporter (DAT) “inverse agonism” e Anovel 66 2 67 3 hypothesis to explain the enigmatic pharmacology of cocaine 68 4 * 69 5 Q5 David J. Heal , Jane Gosden, Sharon L. Smith 70 6 71 RenaSci Limited, BioCity, Pennyfoot Street, Nottingham NG1 1GF, UK 7 72 8 73 9 article info abstract 74 10 75 11 76 Article history: The long held view is cocaine's pharmacological effects are mediated by monoamine reuptake inhibition. 12 Available online xxx However, drugs with rapid brain penetration like sibutramine, bupropion, mazindol and tesofensine, 77 13 which are equal to or more potent than cocaine as dopamine reuptake inhibitors, produce no discernable 78 14 Keywords: subjective effects such as drug “highs” or euphoria in drug-experienced human volunteers. Moreover 79 15 Cocaine they are dysphoric and aversive when given at high doses. In vivo experiments in animals demonstrate 80 16 Dopamine reuptake inhibitor that cocaine's monoaminergic pharmacology is profoundly different from that of other prescribed 81 Dopamine releasing agent 17 monoamine reuptake inhibitors, with the exception of methylphenidate. These findings led us to 82 Dopamine transporter fi 18 Inverse agonist conclude that the highly unusual, stimulant pro le of cocaine and related compounds, eg methylphe- 83 19 DAT inverse agonist nidate, is not mediated by monoamine reuptake inhibition alone. 84 We describe the experimental findings which suggest cocaine serves as a negative allosteric 20 Novel mechanism 85 21 modulator to alter the function of the dopamine reuptake transporter (DAT) and reverse its direction of fi 86 22 transport.
    [Show full text]
  • Y-BOCS™ (Yale-Brown Obsessive-Compulsive Scale) Principal Developer: Wayne K. Goodman, M.D. Co-Developers: Steven A. Rasmussen
    FIRST EDITION 9/89 (Revised 05/20) Y-BOCS™ (Yale-Brown Obsessive-Compulsive Scale) Principal Developer: Wayne K. Goodman, M.D. Co-developers: Steven A. Rasmussen, M.D. Lawrence H. Price, M.D. Eric A. Storch, PhD. Investigators interested in using this rating scale should contact Dr. Goodman at <[email protected]>. © 1989, 2017 Wayne Goodman Additional information regarding the development, use, and psychometric properties of the Y-BOCS™ can be found in Goodman WK, Price LH, Rasmussen SA, et al.: The Yale-Brown Obsessive Compulsive Scale: Part I. Development, use, and reliability. Arch Gen Psychiatry (46:1006-1011, 1989). and Goodman WK, Price LH, Rasmussen SA, et al.: The Yale-Brown Obsessive Compulsive Scale): Part II. Validity. Arch Gen Psychiatry (46:1012-1016, 1989). Copies of a version of the Y-BOCS™ modified for use in children, the Children's Y-BOCS™ (CY-BOCS™) (Goodman WK, Rasmussen SA, & Price LH,), or the second editions of the Y-BOCS-II™ and CY-BOCS-II™ are available from Dr. Goodman on request. Y-BOCS™ General Instructions This rating scale is designed to rate the severity and record the types of symptoms in a patient diagnosed with obsessive- compulsive disorder (OCD). In general, the items depend on the patient's report; however, the final rating is based on the clinical judgment of the interviewer. Rate the characteristics of each item during the prior week up until and including the time of the interview. Scores should reflect the average (mean) occurrence of each item for the entire week. This rating scale is intended for use as a semi-structured interview.
    [Show full text]
  • Self-Ambivalence in Obsessive-Compulsive Disorder
    Self-Ambivalence in Obsessive-Compulsive Disorder Sunil S Bhar Submitted in total fulfilment of the requirements of the degree of Doctor of Philosophy July, 2004 Produced on acid-free paper Department of Psychology University of Melbourne ii iii Abstract According to the cognitive model, Obsessive-compulsive disorder (OCD) is maintained by various belief factors such as an inflated sense of responsibility, perfectionism and an overestimation about the importance of thoughts. Despite much support for this hypothesis, there is a lack of understanding about the role of self-concept in the maintenance or treatment of OCD. Guidano and Liotti (1983) suggest that individuals who are ambivalent about their self-worth, personal morality and lovability use perfectionistic and obsessive compulsive behaviours to continuously restore self- esteem. This thesis develops a model of OCD that integrates self-ambivalence in the cognitive model of OCD. Specifically, it explored the hypothesis that the OCD symptoms and the belief factors related to the vulnerability of OCD are mechanisms that provide relief from self- ambivalence. It addressed three questions. First, is self-ambivalence related to OCD symptoms and OCD-related beliefs? Second, to what extent is self-ambivalence specific to OCD, compared to other anxiety disorders? Third, to what extent is self-ambivalence important in accounting for response and relapse of OCD to psychological interventions? In order to explore these questions, a questionnaire measuring self- ambivalence was first developed and evaluated. Non clinical and clinical participants were recruited for research. Non-clinical participants (N = 269) comprised undergraduate students (N = 226: mean age = 19.55; SD = 3.27) and community controls (N = 43; mean age = 43.78; SD = 3.92).
    [Show full text]
  • Quick-View Guides
    Appendix A Quick-View Guides Compiled by Jennifer S. Mills 310 APPENDIX A QUICK-VIEW GUIDES 311 312 APPENDIX A QUICK-VIEW GUIDES 313 314 APPENDIX A QUICK-VIEW GUIDES 315 316 APPENDIX A QUICK-VIEW GUIDES 317 Appendix B Reprinted Measures Measures for Anxiety and Related Constructs 322 APPENDIX B Anxiety Control Questionnaire (ACQ) Listed below are a number of statements describing a set of beliefs. Please read each statement carefully and, on the 0–5 scale below, indicate how much you think each statement is typical of you. 1. I am usually able to avoid threat quite easily. 2. How well I cope with difficult situations depends on whether I have outside help. 3. When I am put under stress, I am likely to lose control. 4. I can usually stop my anxiety from showing. 5. When I am frightened by something, there is generally nothing I can do. 6. My emotions seem to have a life of their own. 7. There is little I can do to influence people’s judgments of me. 8. Whether I can successfully escape a frightening situation is always a matter of chance with me. 9. I often shake uncontrollably. 10. I can usually put worrisome thoughts out of my mind easily. 11. When I am in a stressful situation, I am able to stop myself from breathing too hard. 12. I can usually influence the degree to which a situation is potentially threatening to me. 13. I am able to control my level of anxiety. 14. There is little I can do to change frightening events.
    [Show full text]
  • Double Blind Randomized Controlled Trial of Deep Brain Stimulation for Obsessive- Compulsive Disorder: Clinical Trial Design
    UC San Diego UC San Diego Previously Published Works Title Double blind randomized controlled trial of deep brain stimulation for obsessive- compulsive disorder: Clinical trial design. Permalink https://escholarship.org/uc/item/93m0r1w4 Authors McLaughlin, Nicole CR Dougherty, Darin D Eskandar, Emad et al. Publication Date 2021-06-05 DOI 10.1016/j.conctc.2021.100785 Peer reviewed eScholarship.org Powered by the California Digital Library University of California Contemporary Clinical Trials Communications 22 (2021) 100785 Contents lists available at ScienceDirect Contemporary Clinical Trials Communications journal homepage: www.elsevier.com/locate/conctc Double blind randomized controlled trial of deep brain stimulation for obsessive-compulsive disorder: Clinical trial design Nicole C.R. McLaughlin a,b,*, Darin D. Dougherty c,d, Emad Eskandar c,d,1,2, Herbert Ward e, Kelly D. Foote f, Donald A. Malone g, Andre Machado g, William Wong h, Mark Sedrak i, Wayne Goodman j,3, Brian H. Kopell j, Fuad Issa k, Donald C. Shields l, Osama A. Abulseoud m, Kendall Lee n, Mark A. Frye n, Alik S. Widge c,d,o,4, Thilo Deckersbach p, Michael S. Okun f, Dawn Bowers q, Russell M. Bauer q, Dana Mason e, Cynthia S. Kubu g, Ivan Bernstein h, Kyle Lapidus r, David L. Rosenthal j,5, Robert L. Jenkins k, Cynthia Read a, Paul F. Malloy a,b, Stephen Salloway a,b, David R. Strong s, Richard N. Jones b, Steven A. Rasmussen a,b, Benjamin D. Greenberg a,b,t a Butler Hospital, 345 Blackstone Blvd, Providence, RI, 02906, USA b Alpert Medical School of Brown University,
    [Show full text]
  • Y-BOCS Has Become the Gold Standard for Rating Symptom Severity in Patients with Obsessive-Compulsive Disorder (OCD)
    © Goodman, Rasmussen, Price, & Storch, 2011 CCYY--BBOOCCSS--IIII CClliinniiccaall VVeerrssiioonn By the Principal Developers of the Yale-Brown Obsessive Compulsive Scale, Yale-Brown Obsessive Compulsive Scale-Second Edition, and Children's Yale-Brown Obsessive Compulsive Scale WAYNE K. GOODMAN, M.D.* STEVEN A. RASMUSSEN, M.D.† LAWRENCE H. PRICE, M.D.† ERIC A. STORCH, Ph.D.‡ *Department of Psychiatry Mount Sinai School of Medicine †Department Of Psychiatry and Human Behavior Brown University School of Medicine ‡ Department of Pediatrics University of South Florida © Goodman, Rasmussen, Price, & Storch, 2011 Individuals or organizations interested in using this rating scale should contact Dr. Goodman by email: <[email protected]>. INTRODUCTION TO THE 2011 REVISION Since its introduction in 1986, the Y-BOCS has become the gold standard for rating symptom severity in patients with obsessive-compulsive disorder (OCD). Shortly after its inception, the Children's Yale-Brown Obsessive-Compulsive Scale was created using the Y-BOCS structure. Like its adult counterpart, the CY- BOCS has been used as a primary outcome in virtually every major clinical trial involving youth with OCD. It has been translated into multiple languages and remains the standard for assessing symptom severity and treatment response. Despite this broad range of acceptance, over two decades of experience taught us that there is still room for improvement. Accordingly, we revised and created the CY-BOCS-II to address a number of issues that are reviewed below. The Y-BOCS-II
    [Show full text]
  • World of Cognitive Enhancers
    ORIGINAL RESEARCH published: 11 September 2020 doi: 10.3389/fpsyt.2020.546796 The Psychonauts’ World of Cognitive Enhancers Flavia Napoletano 1,2, Fabrizio Schifano 2*, John Martin Corkery 2, Amira Guirguis 2,3, Davide Arillotta 2,4, Caroline Zangani 2,5 and Alessandro Vento 6,7,8 1 Department of Mental Health, Homerton University Hospital, East London Foundation Trust, London, United Kingdom, 2 Psychopharmacology, Drug Misuse, and Novel Psychoactive Substances Research Unit, School of Life and Medical Sciences, University of Hertfordshire, Hatfield, United Kingdom, 3 Swansea University Medical School, Institute of Life Sciences 2, Swansea University, Swansea, United Kingdom, 4 Psychiatry Unit, Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy, 5 Department of Health Sciences, University of Milan, Milan, Italy, 6 Department of Mental Health, Addictions’ Observatory (ODDPSS), Rome, Italy, 7 Department of Mental Health, Guglielmo Marconi” University, Rome, Italy, 8 Department of Mental Health, ASL Roma 2, Rome, Italy Background: There is growing availability of novel psychoactive substances (NPS), including cognitive enhancers (CEs) which can be used in the treatment of certain mental health disorders. While treating cognitive deficit symptoms in neuropsychiatric or neurodegenerative disorders using CEs might have significant benefits for patients, the increasing recreational use of these substances by healthy individuals raises many clinical, medico-legal, and ethical issues. Moreover, it has become very challenging for clinicians to Edited by: keep up-to-date with CEs currently available as comprehensive official lists do not exist. Simona Pichini, Methods: Using a web crawler (NPSfinder®), the present study aimed at assessing National Institute of Health (ISS), Italy Reviewed by: psychonaut fora/platforms to better understand the online situation regarding CEs.
    [Show full text]
  • DOPAMINE TRANSPORTER in ALCOHOLISM a SPET Study
    DOPAMINE TRANSPORTER IN PEKKA ALCOHOLISM LAINE A SPET study Departments of Psychiatry and Clinical Chemistry, University of Oulu Department of Forensic Psychiatry, University of Kuopio Department of Clinical Physiology and Nuclear Medicine, University of Helsinki OULU 2001 PEKKA LAINE DOPAMINE TRANSPORTER IN ALCOHOLISM A SPET study Academic Dissertation to be presented with the assent of the Faculty of Medicine, University of Oulu, for public discussion in the Väinö Pääkkönen Hall of the Department of Psychiatry (Peltolantie 5), on November 30th, 2001, at 12 noon. OULUN YLIOPISTO, OULU 2001 Copyright © 2001 University of Oulu, 2001 Manuscript received 12 October 2001 Manuscript accepted 16 October 2001 Communicated by Professor Esa Korpi Professor Matti Virkkunen ISBN 951-42-6527-0 (URL: http://herkules.oulu.fi/isbn9514265270/) ALSO AVAILABLE IN PRINTED FORMAT ISBN 951-42-6526-2 ISSN 0355-3221 (URL: http://herkules.oulu.fi/issn03553221/) OULU UNIVERSITY PRESS OULU 2001 Laine, Pekka, Dopamine transporter in alcoholism A SPET study Department of Clinical Chemistry, Division of Nuclear Medicine, University of Oulu, P.O.Box 5000, FIN-90014 University of Oulu, Finland, Department of Forensic Psychiatry, University of Kuopio, , FIN-70211 University of Kuopio, Finland, Department of Clinical Physiology and Nuclear Medicine, Division of Nuclear Medicine, University of Helsinki, P.O. Box 340, FIN-00029 Helsinki, Finland, Department of Psychiatry, University of Oulu, P.O.Box 5000, FIN-90014 University of Oulu, Finland 2001 Oulu, Finland (Manuscript received 12 October 2001) Abstract A large body of animal studies indicates that reinforcement from alcohol is associated with dopaminergic neurotransmission in the mesocorticolimbic pathway. However, as most psychiatric phenomena cannot be studied with animals, human studies are needed.
    [Show full text]
  • The Pharmacology of an Agonist Medication to Treat Stimulant Use Disorder
    Virginia Commonwealth University VCU Scholars Compass Theses and Dissertations Graduate School 2017 The Pharmacology of an Agonist Medication to Treat Stimulant Use Disorder Amy Johnson johnsonar24 Follow this and additional works at: https://scholarscompass.vcu.edu/etd © Amy Johnson Downloaded from https://scholarscompass.vcu.edu/etd/5177 This Dissertation is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It has been accepted for inclusion in Theses and Dissertations by an authorized administrator of VCU Scholars Compass. For more information, please contact [email protected]. © Amy R. Johnson 2017 All Rights Reserved The Pharmacology of an Agonist Medication to Treat Stimulant Use Disorder A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy at Virginia Commonwealth University by Amy R. Johnson Bachelor of Science, University of Wisconsin - Eau Claire, 2013 Advisor: S. Stevens Negus, PhD Professor of Pharmacology and Toxicology Virginia Commonwealth University Virginia Commonwealth University Richmond, VA November, 2017 Acknowledgements Thank you to all the people who made this dissertation possible. I would like to thank my family for their support and belief in me. Many thanks to my dissertation advisor, Steve Negus, for his guidance, knowledge, patience, and encouragement. Thank you to Katherine Nicholson and Matthew Banks, each of whom guided me through a different procedure through the course of my research and served on my committee. Thanks to my remaining committee members, Lori Keyser-Marcus and Jose Eltit, for their time and commitment to my project. Thank you to my entire committee for helping to develop and mold me as a scientist.
    [Show full text]
  • Mechanisms of Cocaine Abuse and Toxicity
    Mechanisms of Cocaine Abuse and Toxicity U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES • Public Health Service • Alcohol, Drug Abuse, and Mental Health Administration I Mechanisms of Cocaine Abuse and Toxicity Editors: Doris Clouet, Ph.D. Khursheed Asghar, Ph.D. Roger Brown, Ph.D. Division of Preclinical Research National Institute on Drug Abuse NIDA Research Monograph 88 1988 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Alcohol, Drug Abuse, and Mental Health Administration National Institute on Drug Abuse 5600 Fishers Lane Rockville, MD 20857 For sale by the Superintendent of Documents, U.S. Government Printing Office Washington, DC 20402 NIDA Research Monographs are prepared by the research divisions of the National Institute on Drug Abuse and published by its Office of Science. The primary objective of the series is to provide critical reviews of research problem areas and techniques, the content of state-of-the-art conferences, and integrative research reviews. Its dual publication emphasis is rapid and targeted dissemination to the scientific and professional community. Editorial Advisors MARTIN W. ADLER, Ph.D. MARY L. JACOBSON Temple University School of Medicine National Federation of Parents for Philadelphia,Pennsylvania Drug-Free Youth Omaha, Nebraska SYDNEY ARCHER, Ph.D. Rensselaer Polytechnic lnstitute Troy, New York REESE T. JONES, M.D. Langley Porter Neuropsychiatric lnstitute RICHARD E. BELLEVILLE, Ph.D. San Francisco, California NB Associates, Health Sciences RockviIle, Maryland DENISE KANDEL, Ph.D. KARST J. BESTEMAN College of Physicians and Surgeons of Alcohol and Drug Problems Association Columbia University of North America New York, New York Washington, D.C. GILBERT J.
    [Show full text]
  • CURRICULUM VITAE NAME: Wayne K. Goodman, MD. ADDRESS: Department of Psychiatry University of Florida College of Medicine Mcknigh
    CURRICULUM VITAE NAME: Wayne K. Goodman, MD. ADDRESS: Department of Psychiatry University of Florida College of Medicine McKnight Brain Institute, Suite L4-100 100 Newell Drive Gainesville, FL 32611 ------------------------------------------------------------ --------------------------- PERSONAL --------------------- DATA: ----------------------------------------------------------- CAREER: 1998- Chairman, Department of Psychiatry, University of Florida College of Medicine 1998- Psychiatrist-in-Chief, Shands Healthcare, Gainesville, FL 1997-1998 Interim Chairman, Department of Psychiatry, University of Florida College of Medicine 1997-1999 Associate Chairman, Department of Psychiatry, University of Florida, Jacksonville, FL 1993-1997 Director, Psychiatric Specialty Clinics, Shands Hospital at the University of Florida College of Medicine 1993- Chief, Obsessive-Compulsive and Tourette's Disorders Clinic, Department of Psychiatry, University of Florida College of Medicine 1993-2001 Director, Clinical Trials Program, Department of Psychiatry, University of Florida College of Medicine 1993- Professor (Tenured), Department of Psychiatry, University of Florida College of Medicine 1992-1993 Associate Professor, Department of Psychiatry, Yale University School of Medicine 1990-1993 Associate Unit Chief, Clinical Neuroscience Research Unit, Yale University School of Medicine 1986-1992 Assistant Professor, Department of Psychiatry, Yale University School of Medicine 1985-1992 Chief and founder, Obsessive Compulsive Disorder Clinic, Yale University
    [Show full text]
  • Adrenergic and Glutamergic Receptor Gene Expression
    ADRENERGIC AND GLUTAMERGIC RECEPTOR GENE EXPRESSION AND THEIR FUNCTIONAL REGULATION IN THE CEREBRAL CORTEX OF HYPOXIA INDUCED NEONATAL RATS: ROLE OF OXYGEN, EPINEPHRINE AND GLUCOSE SUPPLEMENTATION THESIS SUBMITTED IN PARTIAL FULFILMENT OF THE REQUIREMENTS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY IN BIOTECHNOLOGY UNDER THE FACtJLTY Of. SCIENCE OF COCHlN llNIVERSITY OF SCIENCE AND TECHNOLOGY BY FINLA CHATHU DEPARTMENT OF BIOTECHNOLOGY COCHIN UNIVERSITY OF SCIENCE AND TECHNOLOGY COCHIN - 682 022. KERALA, INDIA. FEBRUARY 2007 DEPARTMENT OF BIOTECHNOLOGY COCHIN UNIVERSITY Of' SCIENCE AND TECHNOLOGY COCHIf- 6IZ GZJ, ItID&A ....: 04I4-U7ut7 tol. oe-Ul1CH (I.) IIrlb: M41V 114ZJ r-t: It tell. et K In, pet ........OD... fa: " ......157U61. J577595 DR. C.S._LOSE HEAD DIRECTOR, CENTRE FOR NWROSCIEHCE This is 10 certify that the thesis entitled "ADRINERGIC AND GLUT.uR.RGIC UCEI'TOR GRNE IXPRl:SSION AND THEIR J'UNCflONAL RlGULA.'nON IN mE Cl.UBRAL coarex OF HYPOXIA INDUCltD NWNATAL RATS: ROLE O' OXYGEN. UINIPHRlNE AND GUJCOSE SUPPLEMJ:NTATION'" is a bonafide record of the resean::h work carried out by Ms. Fial. Cbathu.. under my guidance and supervision in the Department of Biotec:bnology. Cochin Uaiversity of Science and Tecb.nology and that DO pan thereof has been presented for theaward ofany other degree. Cochin 682 022 2-02-07 Or. C.S. PAUlO SE M se. Ph.D. FIM$A. FGSI DIRECTOR, CE NTRF t · <;r-IENCE HEAD. DEFT. C ..... LOGY Cochin Unlvers .yor ~ ... Technology Cochin·682 012, Ke rclc, India DECLARATION I hereby declare that this thesis entitled "ADRENERGIC AND GLUTAMERGIC RECEPTOR GENE EXPRESSION AND THEIR FUNCTIONAL REGULATION IN THE CEREBRAL CORTEX OF HYPOXIA INDUCED NEONATAL RATS: ROLE OF OXYGEN, EPINEPHRINE AND GLUCOSE SUPPLEMENTATION" is based on the original research carried out by me at the Department of Biotechnology.
    [Show full text]